ES2159318T3 - Inhibidores de la proteina quinasa c. - Google Patents

Inhibidores de la proteina quinasa c.

Info

Publication number
ES2159318T3
ES2159318T3 ES95923985T ES95923985T ES2159318T3 ES 2159318 T3 ES2159318 T3 ES 2159318T3 ES 95923985 T ES95923985 T ES 95923985T ES 95923985 T ES95923985 T ES 95923985T ES 2159318 T3 ES2159318 T3 ES 2159318T3
Authority
ES
Spain
Prior art keywords
beta
inhibitors
isozyme
protein kinase
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95923985T
Other languages
English (en)
Inventor
James Ronald Gillig
Michael Robert Jirousek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/263,912 external-priority patent/US5481003A/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2159318T3 publication Critical patent/ES2159318T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCION DESCRIBE COMPOSICIONES QUE SON POTENTES INHIBIDORES SELECTIVOS DE ISOZIMA, DE ISOZIMA BETA-1 Y BETA-2 DE LA PROTEINA CINASA C. ESTAS COMPOSICIONES SON 3,4-DI-[[]3''(()1''SUSTITUIDO())-INDOLIL[]]-1H-PIRROL-2,5-DIONAS, QUE PUEDEN SER DESCRITAS MAS COMUNMENTE COMO 3,4-BIS(()3''-INDOLIL()) MALEIMIDAS. ADEMAS, COMO INHIBIDORES SELECTIVOS DE ISOZIMA DE LAS ISOZIMAS BETA-1 Y BETA-2, LAS COMPOSICIONES SON TERAPEUTICAMENTE UTILES EN EL TRATAMIENTO DE CONDICIONES ASOCIADAS CON DIABETES MELLITUS Y SUS COMPLICACIONES, ASI COMO OTROS ESTADOS DE ENFERMEDADES ASOCIADOS CON UNA ELEVACION DE ESTAS ISOZIMAS.
ES95923985T 1994-06-22 1995-06-19 Inhibidores de la proteina quinasa c. Expired - Lifetime ES2159318T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/263,912 US5481003A (en) 1994-06-22 1994-06-22 Protein kinase C inhibitors
US08/404,218 US5491242A (en) 1994-06-22 1995-03-15 Protein kinase C inhibitors

Publications (1)

Publication Number Publication Date
ES2159318T3 true ES2159318T3 (es) 2001-10-01

Family

ID=26950130

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95923985T Expired - Lifetime ES2159318T3 (es) 1994-06-22 1995-06-19 Inhibidores de la proteina quinasa c.

Country Status (11)

Country Link
US (1) US5491242A (es)
EP (1) EP0766682B1 (es)
JP (1) JPH10502910A (es)
AT (1) ATE203991T1 (es)
AU (1) AU2866995A (es)
DE (1) DE69522109T2 (es)
DK (1) DK0766682T3 (es)
ES (1) ES2159318T3 (es)
GR (1) GR3037074T3 (es)
PT (1) PT766682E (es)
WO (1) WO1995035294A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0888339A4 (en) * 1996-03-20 2001-02-28 Lilly Co Eli SYNTHESIS OF INDOLYLMALEINIMIDES
EP0915698A4 (en) 1996-05-01 1999-08-11 Lilly Co Eli TREATMENT PROCEDURE FOR VEGF-RELATED DISEASES
US6232299B1 (en) 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
UA54427C2 (uk) * 1996-05-01 2003-03-17 Елі Ліллі Енд Компані Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту
US6093709A (en) * 1996-08-22 2000-07-25 Eli Lilly And Company Therapeutic treatment for sexual dysfunctions
US5962446A (en) * 1996-08-30 1999-10-05 Eli Lilly And Company Therapetutic treatment for human T cell lymphotrophic virus type 1 infection
US6107327A (en) * 1996-08-30 2000-08-22 Eli Lilly And Company Therapeutic treatment for HIV infection
US6093740A (en) * 1997-04-30 2000-07-25 Eli Lilly And Company Therapeutic treatment for skin disorders
CA2227688C (en) 1998-01-16 2007-07-31 James W. Critchfield Methods and compositions for inhibition of viral replication
US6103713A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for autoimmune diseases
US6291446B1 (en) 1998-03-05 2001-09-18 Eli Lilly And Company Therapeutic treatment for cytomegalovirus infection
US6225301B1 (en) 1998-03-05 2001-05-01 Eli Lilly And Company Therapeutic treatment for renal dysfunction
US6103712A (en) * 1998-03-05 2000-08-15 Eli Lilly And Company Therapeutic treatment for asthma
US6013646A (en) * 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US6492406B1 (en) * 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
US6284783B1 (en) 1999-06-09 2001-09-04 The Uab Research Foundation Use of bisindolylmaleimide compounds to induce Fas-mediated apoptosis
DE10244453A1 (de) 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US20040175384A1 (en) * 2003-12-12 2004-09-09 Mohapatra Shyam S. Protein kinase C as a target for the treatment of respiratory syncytial virus
US8592368B2 (en) 2003-12-19 2013-11-26 University Of South Florida JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
GB0513881D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0329667D0 (en) 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
US8158586B2 (en) * 2005-04-11 2012-04-17 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
AR056517A1 (es) 2005-09-16 2007-10-10 Schering Corp Composiciones y metodos farmaceuticos utilizando temozolomida y un inhibidor de la proteina quinasa
GB0605691D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
ES2410955T3 (es) 2006-12-19 2013-07-04 Novartis Ag Derivados de indolilmaleimida como inhibidores de la quinasa
CN104398508B (zh) * 2014-11-28 2017-06-13 上海交通大学 双吲哚马来酰亚胺衍生物在制备治疗慢性粒细胞白血病药物中的应用
CN104693198B (zh) * 2014-12-13 2017-03-08 浙江工业大学 3‑(1,2,4‑三氮唑并[4,3‑a]吡啶‑3‑基)‑4‑(1H‑吲哚‑3‑基)马来酰亚胺类衍生物及其制备方法和应用
CN110526903B (zh) * 2016-06-01 2021-12-10 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4785085A (en) * 1986-11-21 1988-11-15 Bristol-Myers Company Rebeccamycin analogs
DE3752123T2 (de) * 1987-03-09 1998-05-14 Kyowa Hakko Kogyo Kk Derivate des physiologisch aktiven mittels k-252
DE3803620A1 (de) * 1988-02-06 1989-08-17 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
MC2096A1 (fr) * 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
DE3914764A1 (de) * 1989-05-05 1990-11-08 Goedecke Ag Maleinimid-derivate und deren verwendung als arzneimittel
CA2015996C (en) * 1989-05-05 2001-08-28 Hartmut Osswald Bis-(1h-indol-3-yl)-maleinimide derivatives and their use as pharmaceuticals
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
DE3942296A1 (de) * 1989-12-21 1991-06-27 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung
DE4005969A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005970A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
GB9123396D0 (en) * 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
WO1993018765A1 (en) * 1992-03-20 1993-09-30 The Wellcome Foundation Limited Indole derivatives with antiviral activity
DE4217964A1 (de) * 1992-05-30 1993-12-02 Goedecke Ag Indolocarbazol-Imide und deren Verwendung
AU5100393A (en) * 1992-09-25 1994-04-26 Schering Corporation Diindolo compounds and pharmaceutical compositions containing them
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren

Also Published As

Publication number Publication date
US5491242A (en) 1996-02-13
GR3037074T3 (en) 2002-01-31
DE69522109D1 (de) 2001-09-13
EP0766682B1 (en) 2001-08-08
EP0766682A1 (en) 1997-04-09
PT766682E (pt) 2001-11-30
WO1995035294A1 (en) 1995-12-28
JPH10502910A (ja) 1998-03-17
AU2866995A (en) 1996-01-15
EP0766682A4 (en) 1997-09-10
ATE203991T1 (de) 2001-08-15
DE69522109T2 (de) 2002-04-18
DK0766682T3 (da) 2001-10-08

Similar Documents

Publication Publication Date Title
ES2159318T3 (es) Inhibidores de la proteina quinasa c.
PT817627E (pt) Inibidores da proteina cinase c
ATE234092T1 (de) 2-alkylpyrrolidine
CA2376596A1 (en) Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
AU2002366641A1 (en) Methods for inhibiting ocular processes
WO2001079460A3 (en) Polypeptides having haloperoxidase activity
WO2003057837A8 (en) Methods for using anti-muc18 antibodies
NZ324921A (en) Cathepsin K crystal structure and methods of identifying inhibitors of this protease
WO2001079458A3 (en) Polypeptides having haloperoxidase activity
AU7585598A (en) Raf kinase inhibitors
BG101966A (en) Application of 1l-agonist for the treatment of lack of urine retention
ES2088771A1 (es) Metodo para mejorar la acividad reproductora en verracos utilizando alimento para los verracos reproductores.
DE3861462D1 (de) Gasfeuerzeugstruktur, geeignet zur andrueckmontage seiner hauptteile.
ES2195655T3 (es) Procedimiento para tratar fiebre hemorragica virica con proteina c.
TR199902131A3 (tr) Kükürt, metal ve asfalten içeren hidrokarbon besleme maddelerinin kalitesini yükseltmek için yöntem ve cihaz
DE59605545D1 (de) Alkoholhaltige instant-getränkemischung, ihre herstellung und verwendung
EP0972012A4 (en) IMMUNOSUPPRESSION
WO2002061430A3 (en) Methods and reagents for treating autoimmune disorders
WO1999049037A3 (en) Protein phosphatase-related molecules
BR9915572A (pt) Processo de tratamento de doença de célula falciforme e talassemia
BR9915317A (pt) Método de tratar trombocitopenia induzida por heparina
WO2000009104A3 (en) Use of sulfonamides for treating vision and memory disorders
WO2000009108A3 (en) Compositions and uses for vision and memory disorders
WO1999053091A3 (de) Gdnf-kodierende dna, teile davon und gdnf-varianten
NL1000068A1 (nl) Afsluiter.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 766682

Country of ref document: ES